drugset / Trial / NCT01430455

Tranylcypromine Treatment of Bipolar Depression

NCT01430455

Phase 4 Completed 7 enrolled New York State Psychiatric Institute
NaSingle-groupOpen-labelTreatment

Summary

This study seeks to investigate whether tranylcypromine (Parnate®) might be an effective treatment of bipolar depression. New treatments are needed, as there is little evidence that standard antidepressants are effective in treating this condition, and the two antipsychotic medications that have indications for bipolar depression can cause substantial side effects. This study will focus specifically on currently depressed outpatients having a bipolar history for whom at least one standard antidepressant medication was ineffective. Patients will be treated openly with tranylcypromine for 8-10 months, depending on treatment response.

Timeline

Start
2011-11
Primary completion
2014-02
Completion
2014-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Tranylcypromine Small molecule 10 mg
Subject Tranylcypromine Small molecule 120 mg

Indications